TRX 1 - Tolerx
Alternative Names: Anti-CD4 monoclonal antibody - Tolerx; MTRX 1011A; RG 7424; TRX1 - TolerxLatest Information Update: 05 Nov 2023
At a glance
- Originator University of Oxford
- Developer Genentech; Tolerx
- Class Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors; CD45 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cutaneous lupus erythematosus; Rheumatoid arthritis
Most Recent Events
- 07 Oct 2011 Discontinued - Phase-I for Autoimmune disorders in United Kingdom (Parenteral)
- 07 Oct 2011 Discontinued - Phase-I for Cutaneous lupus erythematosus in USA (Parenteral)
- 05 Aug 2008 Genentech initiates enrolment in a phase I trial of MTRX1011A (a modified version of TRX 1) in the US